Apr 26, 2023 / 07:00PM GMT
Stephen Douglas Willey - Stifel, Nicolaus & Company, Incorporated, Research Division - Director
All right. I'm Stephen Willey, one of the senior biotech analysts here at Stifel. I'm very glad to have with us presenting from IGM Biosciences CEO, Fred Schwarzer. Fred, thanks for doing this today. This is just going to be a Q&A format for everyone who's listening. There is a chat function if you have questions that you can populate those questions into. We'll try to get the math and answered. Before we get into Q&A here, Fred, I'm not sure if you want to make any kind of opening statements.
Questions and Answers:
Fred M. Schwarzer - IGM Biosciences, Inc. - CEO, President & DirectorWell, first, thanks for inviting me to participate and it's been a good conference. So I really appreciate the opportunity to talk about IGM. I think I would say that we're very excited about our DR5 program moving into the randomized clinical trial here to test 3 mg per kg and 10 mg per kg against control, FOLFIRI plus bev in both cases. And we're also really
Trustpilot
